Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in LXEO held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 6.2M | $35.5M | +29.8% | 7.876% | 0.73% |
| 2 | BlackRock, Inc. | 5.1M | $29.3M | +4.1% | 6.509% | 0.00% |
| 3 | Affinity Asset Advisors, LLC | 5.1M | $29.0M | +57.8% | 6.432% | 1.69% |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 5.0M | $28.7M | 0.0% | 6.368% | 0.30% |
| 5 | JANUS HENDERSON GROUP PLC | 5.0M | $28.5M | -9.7% | 6.338% | 0.01% |
| 6 | Vestal Point Capital, LP | 4.5M | $25.7M | 0.0% | 5.699% | 0.72% |
| 7 | Frazier Life Sciences Management, L.P. | 4.4M | $25.4M | 0.0% | 5.635% | 0.65% |
| 8 | CITADEL ADVISORS LLC | 3.8M | $22.1M | +1.9% | 4.898% | 0.01% |
| 9 | ORBIMED ADVISORS LLC | 3.6M | $20.7M | +69.5% | 4.588% | 0.44% |
| 10 | STATE STREET CORP | 3.6M | $20.5M | +11.9% | 4.544% | 0.00% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0M | $17.3M | — | 3.830% | 0.00% |
| 12 | Woodline Partners LP | 2.8M | $15.8M | -14.0% | 3.503% | 0.06% |
| 13 | GOLDMAN SACHS GROUP INC | 1.9M | $11.2M | +149.4% | 2.483% | 0.00% |
| 14 | Avoro Capital Advisors LLC | 1.9M | $10.8M | -43.2% | 2.388% | 0.11% |
| 15 | Point72 Asset Management, L.P. | 1.7M | $9.6M | -11.3% | 2.140% | 0.01% |
| 16 | MILLENNIUM MANAGEMENT LLC | 1.6M | $9.3M | +77.6% | 2.054% | 0.01% |
| 17 | BALYASNY ASSET MANAGEMENT LLC | 1.6M | $9.1M | -2.8% | 2.024% | 0.03% |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 1.5M | $8.7M | +4.7% | 1.928% | 0.00% |
| 19 | ADAR1 Capital Management, LLC | 1.5M | $8.4M | +5.3% | 1.869% | 0.53% |
| 20 | SUVRETTA CAPITAL MANAGEMENT, LLC | 1.3M | $7.2M | 0.0% | 1.592% | 0.19% |
| 21 | Nantahala Capital Management, LLC | 1.2M | $6.9M | +20.0% | 1.528% | 0.35% |
| 22 | 683 Capital Management, LLC | 1.2M | $6.9M | +7.1% | 1.528% | 0.53% |
| 23 | DIMENSIONAL FUND ADVISORS LP | 1.1M | $6.3M | +27.9% | 1.405% | 0.00% |
| 24 | Octagon Capital Advisors LP | 1.1M | $6.3M | -36.2% | 1.401% | 0.70% |
| 25 | Spruce Street Capital LP | 929K | $5.3M | +430.6% | 1.183% | 1.28% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in LXEO — a direct measure of their conviction.
Filings activity in LXEO during Q1 2026, grouped by how each filer changed its position.
Institutions that opened a new LXEO position in Q1 2026
Institutions that fully closed their LXEO position in Q1 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 135 | 6.3% | 133.42% | 66.57 pp | $458M | 40% |
| Q4 2025 | 144 | +33% | 199.99% | +104.67 pp | $758M | +132% |
| Q3 2025 | 108 | +20% | 95.32% | +45.98 pp | $327M | +93% |
| Q2 2025 | 90 | +2.3% | 49.34% | +23.04 pp | $169M | +88% |
| Q1 2025 | 88 | 3.3% | 26.30% | 30.14 pp | $90M | 53% |
| Q4 2024 | 91 | +30% | 56.44% | 21.75 pp | $194M | 28% |
| Q3 2024 | 70 | +17% | 78.19% | 45.88 pp | $268M | 37% |
| Q2 2024 | 60 | — | 124.07% | — | $426M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying LXEO stock.
Based on Q1 2026 13F filings, institutional ownership of Lexeo Therapeutics, Inc. Common Stock stands at 133.4%, held across 135 reporting institutions.
Paradigm Biocapital Advisors LP is the largest reported institutional holder of LXEO, with approximately 6,184,134 shares worth $0.04B as of Q1 2026.
Yes — 3 widely-followed marquee investors appear among the top 25 institutional holders of LXEO, including CITADEL ADVISORS LLC, Point72 Asset Management, L.P., MILLENNIUM MANAGEMENT LLC.
Our composite Smart Money Score for LXEO is 44 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
20 institutions opened new positions in LXEO during Q1 2026, while 29 fully exited. 22 added to existing positions and 92 trimmed.
LXEO institutional ownership fell by 66.57 percentage points quarter-over-quarter, with a net change of -9 holders.
The top 10 institutions account for 58.0% of all reported 13F value in LXEO, and the top 25 account for 88.3%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Lexeo Therapeutics, Inc. Common Stock (LXEO) Institutional Ownership